Daan Biotherapeutics and TriOar sign MOU for strategic collaboration on next-generation antibody-drug conjugate development

CAR-T Digest - August 2020

17 November 2025: Daan Biotherapeutics and TriOar sign MOU for strategic collaboration on next-generation antibody-drug conjugate development

Daan Biotherapeutics signed an MOU with TriOar to establish a collaborative partnership in the antibody-drug conjugate (ADC) field
The agreement covers cooperation in exchanging antibody-based drug technologies, evaluating ADC candidates, and expanding joint R&D efforts
Both companies aim to share technological and research capabilities to accelerate the development of next-generation ADC therapies
The collaboration aims to integrate advanced target discovery and antibody development capabilities with a specialized ADC platform to accelerate the creation of a globally competitive ADC pipeline
By combining the ADC platform with a wider range of antibody assets, the partnership is expected to strengthen the potential for developing innovative and effective anticancer therapies